Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001) Meeting Abstract
| Authors: | Riely, G. J.; Kris, M. G.; Schwartz, L. H.; Akhurst, T.; Zhao, B.; Milton, D. T.; Moore, E.; Tyson, L.; Pao, W.; Miller, V. A. |
| Abstract Title: | Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001) |
| Meeting Title: | 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 24 |
| Issue: | 18 Suppl. Pt. 1 |
| Meeting Dates: | 2006 Jun 2-6 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2006-06-01 |
| Start Page: | 380S |
| Language: | English |
| ACCESSION: | WOS:000239009402391 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2006.24.18_suppl.7065 |
| Notes: | --- - Meeting Abstract: 7065 - 42nd Annual Meeting of the American-Society-of-Clinical-Oncology - JUN 02-06, 2006 - Atlanta, GA - S - Part 1 - "Source: Wos" |
